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Summary
Better drugs are needed against human cytomegalo-
virus (HCMV), a pathogen responsible for severe dis-
eases in immunocompromised hosts and newborn
children. We investigated whether selective inhibitors
of HCMV replication could be discovered by screening
for compounds that disrupt the interaction between
the accessory subunit of the viral DNA polymerase,
UL44, and the C-terminal 22 residues of the catalytic
subunit. Fromw50,000 small molecules, we identified
5 structurally diverse compounds that not only specif-
ically interfere with this interaction, but also with the
physical and functional interaction of UL44 with full-
length catalytic subunit. These five compounds also
inhibited HCMV replication with sub- to low micromo-
lar potency, and at concentrations up to 500-fold lower
than those at which they exhibited cytotoxicity. These
compounds represent a promising starting point for
the development of anti-HCMV drugs.
Introduction
Protein-protein interactions play a pivotal role in virtually
every biological process, including the replication of
pathogenic viruses in host cells. Several interactions be-
tween viral proteins have been proposed as attractive
targets for antiviral drug discovery, as the exquisite
specificity of such interactions affords the possibility
of interfering with them in a highly selective and effective
manner [1]. We have been investigating one such inter-
action—that between the two subunits of the DNA poly-
merase of human cytomegalovirus (HCMV) [2–4].
HCMV is a ubiquitous herpesvirus. Although it rarely
causes symptomatic disease in immunocompetent indi-
viduals, it is responsible for a variety of severe diseases
in transplant recipients and in AIDS patients, including
pneumonia, gastrointestinal disease, and retinitis [5].
HCMV is also a major cause of congenital malformation
in newborn children, often resulting in deafness and
mental retardation [6]. Antiviral agents currently ap-
proved for the treatment of HCMV infections include
ganciclovir (GCV), foscarnet, and cidofovir, all of which
inhibit the viral DNA polymerase. GCV, which is the
*Correspondence: don_coen@hms.harvard.edumost widely used anti-HCMV drug, and cidofovir are
nucleoside analogs, which function as DNA chain termi-
nators, whereas foscarnet inhibits HCMV DNA polymer-
ase through mimicry of the pyrophosphate product of
polymerization [7]. However, these drugs are limited by
their toxicities, pharmacokinetic drawbacks, and viral
resistance issues [8]. Thus, there is considerable need
for new anti-HCMV compounds.
One obstacle to the inhibition of protein-protein inter-
actions is that these interactions often involve a large
surface area and multiple contacts [9, 10]. However,
several studies have shown that relatively few residues
within these large surfaces can drive binding [11], and
that single substitutions in one subunit of a protein-
protein interface can completely disrupt subunit inter-
actions, or nearly so (e.g., [12]). We have previously
investigated this issue with the HCMV DNA polymerase,
which consists of a 1242 residue catalytic subunit, UL54
[13], and a 433 residue accessory subunit, UL44, which
stimulates long-chain DNA synthesis, presumably by in-
creasing processivity [14, 15]. Both UL54 and UL44 are
essential for HCMV DNA replication [16–18], and the
UL54-UL44 interaction is specific [2]. Additionally, the
C-terminal 22 residues of UL54 are both necessary and
sufficient for binding to UL44 [3]. A peptide correspond-
ing to these residues can both disrupt the physical inter-
action between UL54 and UL44 and specifically inhibit
the stimulation of UL54 activity by the accessory protein
[2]. We found that single substitutions in either UL54 or
UL44 can drastically and specifically disrupt the interac-
tion of these two proteins and their ability to synthesize
long chains of DNA [3, 4]. Taken together, these obser-
vations suggest that a small molecule could specifically
inhibit the UL54-UL44 interaction and HCMV replication.
There are only a few examples of small molecules that
disrupt protein-protein interactions and exert effects in-
side cells (reviewed in [19]). However, we were encour-
aged by the recent identification of a small molecule
(BP5) [20], which specifically inhibits the physical inter-
action between the two subunits of herpes simplex virus
(HSV) type 1 DNA polymerase, UL30 and UL42, which
are homologous to HCMV UL54 and UL44, respectively.
Moreover, BP5 inhibits HSV-1 replication in cell culture,
although it is too cytotoxic to contemplate its clinical use
against HSV. With the considerable need for new anti-
HCMV drugs, the goal of this study was to determine if
we could identify, via high-throughput screening, com-
pounds that could specifically inhibit the UL54-UL44 in-
teraction. These studies led to the discovery of several
small molecules that are substantially more potent for
anti-HCMV activity than for cytoxicity.
Results
Development of an Assay to Identify Small-Molecule
Inhibitors of the UL54-UL44 Interaction
To identify small-molecule inhibitors of the UL54-UL44
interaction, we developed an assay based on fluores-
cence polarization (FP) [21]. In this assay, a peptide cor-
responding to the C-terminal 22 residues of UL54 (here
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192named peptide 1, as in [2]), which was labeled with a flu-
orophore, is mixed with UL44DC290, a truncated protein
that retains all known biochemical activities of full-
length UL44 [4], fused to glutathione S-transferase
(GST-UL44DC290). The unbound labeled peptide tum-
bles relatively rapidly. Thus, if it is excited with polarized
light, by the time emission occurs, the polarization of the
emitted light is low. However, upon binding to GST-
UL44DC290, the peptide would be expected to tumble
much more slowly, so the emitted light would remain
relatively polarized, resulting in an increase in FP, mea-
sured as millipolarization units (mP). Thus, addition of in-
creasing amounts of GST-UL44DC290 to a solution of
3 nM labeled peptide resulted in increasing FP (Fig-
ure 1A). From the data in Figure 1A, a Kd value of
w1 mM was calculated for the interaction between
GST-UL44DC290 and the UL54 peptide. This value is
within 2-fold of that (0.52 mM) previously determined
for GST-UL44DC290 and the corresponding unlabeled
UL54 peptide with isothermal titration calorimetry [3].
As a control, we also examined binding of a mutant
GST-UL44DC290 (I135A), which is severely impaired
for binding to both full-length UL54 and the UL54-
derived peptide [4]. Addition of GST-UL44DC290 I135A
to labeled peptide 1 resulted in only a slight increase in
FP at protein concentrations higher than 17.5 mM (Fig-
ure 1A). Furthermore, no increase in FP was observed
when the labeled peptide was incubated in the presence
either of GST or of a fusion between maltose binding
protein and the HSV-1 homolog of UL44, UL42 (MBP-
UL42DC340). Thus, this assay could specifically and
quantitatively measure interactions between UL44 and
the UL54-derived peptide.
We next investigated whether this assay could detect
a known inhibitor of the UL54-UL44 interaction. To this
end, a binding reaction of 2.5 mM GST-UL44DC290 and
3 nM labeled peptide was titrated with increasing con-
centrations of unlabeled peptide 1 (Figure 1B). This pep-
tide has been shown to inhibit both the physical interac-
tion between UL54 and UL44 and DNA synthesis by the
UL54-UL44 complex [2]. We observed that FP from the
UL44-peptide interaction was inhibited by unlabeled
peptide 1 with a 50% inhibitory concentration (IC50) of
5 mM. This value is of a similar magnitude to that mea-
sured (11 mM) for inhibition of the UL54-UL44 physical in-
teraction by this peptide in an ELISA interaction assay
[2]. A peptide corresponding to the last 36 residues of
HSV-1 UL30 (peptide A), which has been shown to inhibit
the interaction between HSV-1 UL30 and UL42 [22], did
not cause a decrease in FP (Figure 1B). Thus, this assay
could detect specific inhibition of the interaction be-
tween UL44 and the UL54-derived peptide.
High-Throughput Screen
We then used the FP assay and the facilities of the Har-
vard Institute of Chemistry and Cell Biology (ICCB) to
screen the Peakdale (2,816 compounds), Bionet (4,800
compounds), Maybridge (8,800 compounds), and
ChemDiv (28,864 compounds) libraries, and 4,348 com-
pounds out of the 50,000 of the Chembridge Micro-
format library. Thus, we screened a total of 49,628
compounds, each at a concentration of 12.5 mg/ml. As
positive controls for inhibition, reaction mixtures of
GST-UL44DC290 and labeled peptide in the presenceof 3 mM or 20 mM of unlabeled peptide 1 were included
on each screening plate. The criterion for an active com-
pound was one that exhibited an FP value similar to or
lower than that observed in binding reactions of GST-
UL44DC290 and labeled peptide in the presence of
3 mM unlabeled peptide 1. A total of 143 compounds (ap-
proximately 0.3% of the compounds screened) met this
criterion. These compounds were then retested in the
FP assay with GST-UL44DC290 and UL54-derived pep-
tide. They were also assayed, at the same concentration
used during the screen (12.5 mg/ml), in an FP assay that
was used to discover inhibitors of interactions between
HSV-1 DNA polymerase subunits [20]. This assay used
MBP-UL42DC340 and a labeled HSV-1 UL30-derived
peptide [20]. Of the 143 hits, only 25 (0.05% of the com-
pounds screened) were found to specifically inhibit the
UL54 peptide-UL44 but not the UL30-UL42 interaction
in FP assays. Of the other 118 compounds, 97 inhibited
the UL30-UL42 interaction, and 21 were not active in
both assays. Among the 25 specifically active com-
pounds, 21 small molecules, which were designated
AL1 to AL21 (Figure 2), were commercially available
and were purchased for further studies. Among these
compounds, two classes with similar structure are rec-
ognizable: a class composed of AL1, AL2, AL3, and
AL4, and another class composed of AL8 and AL21.
The remaining compounds are not obviously similar.
Figure 1. FP Assay
(A) Increasing concentrations of wild-type GST-UL44DC290 (cir-
cles), of GST-UL44DC290 I135A, a mutant UL44 that does not
bind UL54 (triangles), of GST (squares), or of MBP-UL42DC340 (in-
verted triangles) were added to 3 nM of a fluorescently labeled pep-
tide corresponding to the C-terminal 22 residues of HCMV UL54
(peptide 1), and FP (as millipolarization units, mP) was measured.
(B) Increasing concentrations of unlabeled peptide 1 (circles), or of
peptide A, corresponding to the 36 C-terminal residues of HSV-1
UL30 (squares), were added to reaction mixtures containing
2.5 mM GST-UL44DC290 and 3 nM labeled peptide 1, and FP was
measured.
Selective Anti-HCMV Agents
193Figure 2. Chemical Structures of 21 Com-
pounds Selected from High-Throughput
Screening for Inhibitors of UL44-UL54 Pep-
tide InteractionNone of these molecules was identical to any compound
previously identified in screening at the ICCB for inhibi-
tion of different protein-protein interactions (C. Shamu,
personal communication).
Dose Dependence of Inhibition
Next, we performed dose-response analyses of the inhi-
bition of the UL44-UL54 peptide interaction for each of
the 21 compounds in Figure 2. Of these, nine com-
pounds—AL5, AL6, AL8, AL9, AL10, AL11, AL12, AL18,and AL21—reproducibly exhibited a dose-dependent
reduction in FP, with IC50 values lower than 50 mM
(values ranged from 5 to 30 mM; see Figure 3A and Table
1). Two other compounds, AL13 and AL15, inhibited FP
in a dose-dependent manner, but with higher IC50 values
(50 and 60 mM, respectively; Table 1). The remaining 10
compounds did not reproducibly inhibit UL44-UL54
peptide binding in FP assays in a dose-dependent
manner (Figure 3A and Table 1). As a control, varying
concentrations of the active compounds were alsoFigure 3. Dose Dependence of Inhibition of FP by Selected Compounds
(A) Increasing concentrations of compound AL3, AL5, AL9, AL12, AL18, AL20, and AL21 were added to reaction mixtures containing 2.5 mM
GST-UL44DC290 and 3 nM labeled peptide 1, and FP (as millipolarization units, mP) was measured.
(B) Increasing concentrations of compound AL3, AL5, AL9, AL12, AL18, AL20, and AL21, were added to reaction mixtures containing 7 mM MBP-
UL42DC340 and 5 nM of a fluorescently labeled peptide corresponding to the C-terminal 18 residues of HSV-1 UL30, and FP was measured.
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194Table 1. Summary of Activities of 21 Compounds, Peptide 1, and GCV
Viral Yield Reduction Cytotoxicity
Fluorescence
Polarization
Long-Chain
DNA Synthesis
by UL54/UL44
DNA
Synthesis by
UL54 Alone
ELISA
Interaction
Plaque
Reduction ED50 (mM) CC50 (mM)
Compound IC50 (mM) IC50 (mM) IC50 (mM) IC50 (mM) ED50 (mM) 72 hr 120 hr 24 hr 72 hr 120 hr
AL1 >200 >100 >100 >30 50 >200 >200 >200
AL2 >200 >100 95 >30 90 >200 >200 >200
AL3 >200 >100 >100 >200 >30 >100 80 >200 >200 >200
AL4 >200 >40 >100 >30 >100 >200 >200 >200
AL5a 5 5 >100 7 2.2 1.3 1.0 110 95 75
AL6 30 >40 >100 >30 50 20 20
AL7 >200 >40 >100 >30 >200 60 120
AL8 6 >40 >100 >30 >200 60 60
AL9a 21 10 >100 19 10 8.0 3.1 >200 60 70
AL10 6 >40 >100 0.1 20 1 3
AL11 6 >40 >100 >30 200 12 10
AL12a 19 15 >100 12 1.4 1.9 3.2 >200 40 35
AL13 50 >40 >100 10 >200 17 18
AL14 >200 >40 >100 7.0 >200 30 30
AL15 60 >40 >100 >30 >200 57 55
AL16 >200 >40 >100 5.5 18 2 4
AL17 >200 >40 >100 >30 >200 >200 >200
AL18a 30 5 >100 9 1.1 0.3 0.4 >200 100 200
AL19 >200 >40 >100 4.0 18 1 2
AL20 >200 >100 >100 >200 1.3 4.0 >200 120 200
AL21a 10 5 78 10 3.0 1.7 3.5 >200 45 80
Peptide 1 5 18 >100 15
GCV 1.9 0.9 0.8 >200 200 180
Where no value is presented, the measurement was not done.
a Data for the five compounds that were active in both biochemical and antiviral assays are highlighted in bold.tested in the FP assay for inhibition of the HSV-1 DNA
polymerase subunit interaction [20]. None of the com-
pounds exhibited a dose-dependent reduction in FP in
these assays (Figure 3B and data not shown).
Specific Inhibition of Long-Chain DNA Synthesis
Mediated by UL44
To analyze the ability of the compounds to interfere with
functional UL54-UL44 interactions, we tested their abil-
ity to inhibit long-chain DNA synthesis by UL54 in the
presence of UL44 employing a poly(dA)-oligo(dT)12-18
template-primer. In this assay, no long-chain DNA syn-
thesis was detected in the presence of UL54 alone
(Figure 4A, lane 1), or of GST-UL44DC290 alone (lane
3), while formation of long DNA products was observed
when both UL54 and GST-UL44DC290 were present
(lane 2). An equal concentration (40 mM) of each of the
21 compounds in Figure 2 was initially tested for inhibi-
tion of long-chain DNA synthesis by UL54 and UL44.
Five compounds (AL5, AL9, AL12, AL18, and AL21) se-
verely decreased formation of long DNA products, while
the remaining compounds did not measurably affect
long-chain DNA synthesis (data not shown).
To test the dose dependence of inhibition and quan-
tify the effects on long-chain DNA synthesis, different
doses of the active compounds (AL5, AL9, AL12, AL18,
and AL21) and of four other hits from the screen (AL1,
AL2, AL3, and AL20) were tested. As a control for inhibi-
tion, various concentrations of peptide 1, which was
previously shown to inhibit the rate of incorporation of
nucleotides with an IC50 of 20 mM [2], were also assayed.
These data were quantified by phosphorimager analy-sis, and the IC50 values for inhibition of long-chain
DNA synthesis were calculated (Figure 4B and Table
1). Peptide 1 inhibited long-chain DNA synthesis, with
an IC50 of 18 mM (Figure 4A, lanes 4–8, and Figure 4B).
AL5, AL9, AL12, AL18, and AL21 inhibited formation of
long DNA products in a dose-dependent manner, with
IC50 values ranging from 5 mM to 15 mM (Figures 4A
and 4B and Table 1). In contrast, AL1, AL2, AL3, and
AL20 exhibited little or no inhibition of long-chain DNA
synthesis by UL54 and UL44 (Figures 4A and 4B and
Table 1).
To determine whether the inhibition of long-chain DNA
synthesis could be due to effects on the catalytic activity
of the UL54 subunit, rather than on effects on UL44-me-
diated DNA synthesis, we tested varying concentrations
of each of the 21 compounds in Figure 2 for their effects
on DNA synthesis by UL54 alone by using a filter binding
assay previously described [2]. As summarized in Table
1, only compounds AL2 and AL21 inhibited the activity of
UL54 alone, but only at high concentrations (IC50s of 95
and 78 mM, respectively). However, AL21 inhibited the
activity of UL54 alone much less potently than the activ-
ity of the UL54-UL44 combination (compare IC50 values
reported in Table 1), suggesting a specific effect on
UL44-mediated long-chain DNA synthesis. All other
compounds exhibited little or no inhibition of UL54 cat-
alytic activity (IC50 values > 100 mM; see Table 1).
Specific Inhibition of the Physical Interaction
of UL44 with Full-Length UL54
We next wished to determine, with an ELISA interaction
assay, if the compounds that inhibited the UL44-UL54
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195Figure 4. Effect of Selected Compounds on
Long-Chain DNA Synthesis by UL54 and
UL44
(A) Long-chain DNA synthesis directed by in
vitro-expressed UL54 in the presence or ab-
sence of purified GST-UL44DC290 protein
was assayed by measuring the incorporation
of labeled [32P]TTP wth a poly(dA)-oligo(dT)
template. Examples of long-chain DNA
synthesis directed by UL54 alone (lane 1),
GST-UL44DC290 alone (lane 3), and by
UL54 in the presence of GST-UL44DC290
with no compound added (lane 2) are shown.
Subsequently, long-chain DNA synthesis in
the presence of GST-UL44DC290 was mea-
sured following addition of increasing con-
centrations (6.25, 12.5, 25, 50, 100 mM) of
peptide 1 or of the indicated compounds.
The reaction products were visualized by au-
toradiography following electrophoresis on
a 4% alkaline agarose gel.
(B) Autoradiographs such those in (A) were
quantified by phosphorimager and the per-
centage of signal at each concentration of
compound relative to that in the absence of
added compounds (example given in lane 2
of [A], but different no-compound controls
were performed for each experiment) was
plotted versus the concentration of each
compound tested. Data in (B) represent the
means of values from three independent ex-
periments such as that shown in (A).functional interaction could inhibit the physical interac-
tion of UL44 with full-length UL54. In this assay, binding
between purified baculovirus-expressed UL54 and
UL44, which was tagged with an EEF epitope, was de-
tected with an antibody that recognizes the epitope
tag [2]. This assay was used to test the five compounds
that had specifically inhibited long-chain DNA synthesis
by UL54-UL44 (AL5, AL9, AL12, AL18, and AL21), two
other compounds that had scored as hits in the initial as-
say (AL3 and AL20), and peptide 1 as a control. Peptide 1
exhibited an IC50 for inhibition of the UL54-UL44 interac-
tion of 15 mM, a value similar to that (11 mM) previously
determined by using the same assay [2]. Consistent
with the results of the long-chain DNA synthesis assay,
compounds AL5, AL9, AL12, AL18, and AL21 were
able to interfere with the physical interaction between
UL44 and full-length UL54, with IC50 values ranging
from 7 to 19 mM, whereas compounds AL3 and AL20
did not significantly inhibit the UL54-UL44 interaction
at concentrations up to 200 mM (Figure 5 and Table 1).
Antiviral and Cytotoxic Activity
We then investigated the antiviral effects of the 21 com-
pounds in human foreskin fibroblast (HFF) cells. First,
we tested all 21 compounds in plaque reduction assays,
which entail viral infection at low multiplicity. GCV was
included in these experiments as a control for inhibition.
GCV exhibited a 50% effective dose (ED50) of 1.9 mM,
a value in the range of those previously reported (0.43–
7 mM [23]). AL5, AL9, AL12, AL18, and AL21, the com-
pounds that inhibited both physical and functional inter-
actions between UL54 and UL44 in biochemical assays,
also inhibited plaque formation by HCMV AD169, with
ED50 values from 1.1 to 10 mM (Figure 6A and Table 1).
Although not active in biochemical assays, other com-pounds, namely AL14, AL16, AL19, and AL20, exhibited
activity against virus plaque formation (ED50 values
< 30 mM; Figure 6A and Table 1).
Next, we tested the effects of selected compounds
and of GCV as a control in viral yield assays, which
measure the titer of virus progeny produced following
infection at relatively high multiplicity. In these assays,
the viral titer was measured at two different times points
postinfection: at 72 hr, when the release of virus progeny
is increasing, and at 120 hr, when the titer of virus
progeny after a single cycle of replication reaches
peak levels [24]. Virus titers from untreated infected
cells were 1.2 3 105 PFU (plaque forming units)/ml and
3.9 3 106 PFU/ml at 72 hr and 120 hr postinfection,
Figure 5. Effect of Selected Compounds on the Physical Interac-
tion of UL44 with Full-Length UL54
The interaction between purified baculovirus-expressed UL54 and
UL44 proteins was measured by using an interaction ELISA in the
presence of varying concentrations of AL3, AL5, AL9, AL12, AL18,
AL20, and AL21, and of peptide 1 as a positive control.
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AL21, which were active in the biochemical assays for
inhibition of UL54-UL44 interactions, inhibited virus
yield, with ED50 values at 72 hr postinfection ranging
from 0.3 to 8 mM (Table 1) and with ED50 values at 120
hr postinfection ranging from 0.4 to 3.5 mM (Figure 6B
and Table 1). GCV exhibited an ED50 of 0.9 mM at 72 hr
postinfection and of 0.8 mM at 120 hr postinfection in
these assays. Of the compounds that were inactive for
inhibition in biochemical assays for inhibition of UL54-
UL44 interactions, compound AL20 showed significant
antiviral activity (ED50 = 4.0 mM at 120 hr postinfection),
whereas compounds AL1, AL2, AL3, and AL4 exhibited
little or no effect on HCMV replication (Figure 6B and
Figure 6. Antiviral Activity and Cytotoxicity of Selected Com-
pounds
(A) The effects of AL3, AL5, AL9, AL12, AL18, AL20, AL21, and GCV
as a control, on plaque formation by HCMV strain AD169 were
determined in HFF cells.
(B) The effects of AL3, AL5, AL9, AL12, AL18, AL20, AL21, and GCV
on the yield of HCMV AD169 in HFF cells were determined at 5 days
postinfection in single-cycle growth assays.
(C) The effect of AL3, AL5, AL9, AL12, AL18, AL20, AL21, and GCV
on HFF cell viability were measured by using an XTT assay at 120 hr
following the addition of compound to cell media. The absorbances
measured in the XTT assay were plotted onto a standard curve of
number of cells versus absorbance to calculate the percentage of
viable cells remaining.Table 1). AL18 reduced virus yields by 4–6 logs, while
a 4–5 log reduction in yield was typically observed in
samples treated with GCV at similar concentrations.
AL5 and AL21 reduced virus yield 4–5 logs, while 3–4
log reductions were observed with AL9, AL12, and AL20.
In parallel, we tested the cytotoxicity of all 21 com-
pounds and of GCV in HFF cells for 24, 72, or 120 hr by
using a dye-uptake (XTT; Roche Molecular Biochemi-
cals) assay. The 120 hr assay assessed effects on both
viability and proliferation, while the other assays mainly
assessed effects on viability. GCV exhibited a concen-
tration that causes a decrease of cell viability of 50%
(CC50) around 200 mM (Figure 6C, which shows the 120
hr assay data, and Table 1), a value that is in the range
of those previously reported (40–800 mM [23]). Com-
pounds AL6, AL10, AL11, AL13, AL14, AL16, and AL19
exhibited significant cytotoxicity in this assay. Impor-
tantly, for compounds AL10, AL13, AL14, AL16, and
AL19, the CC50 values were similar to the ED50s mea-
sured in antiviral assays (Table 1). Thus, the effects of
these compounds observed in antiviral assays are likely
due to cytotoxicity rather than to specific antiviral activ-
ity. In contrast, compounds AL5, AL9, AL12, AL18, AL20,
and AL21 showed cytotoxicity at concentrations from 7-
to 500-fold higher than those at which they exhibited an-
tiviral activity (Figure 6C and Table 1). Thus, these small
molecules appear to exhibit selective anti-HCMV activ-
ity. Among these six compounds, five (i.e., AL5, AL9,
AL12, AL18, and AL21) also specifically inhibited physi-
cal and functional interactions between UL54 and UL44.
One compound, AL20, although originally identified in
our screen, was not active in biochemical assays of
UL54-UL44 interactions. Thus, the mechanism of this
compound is likely to be different.
Discussion
In this study, we identified five small molecules with di-
verse structures that selectively inhibit the physical in-
teraction between the subunits of HCMV DNA polymer-
ase and its functional consequences. These compounds
did not detectably inhibit the interaction between the ac-
cessory subunit and the C terminus of the catalytic sub-
unit of HSV-1 DNA polymerase. Nor did they inhibit basal
DNA polymerase activity of the HCMV catalytic subunit
alone, except in one case at high concentrations. These
five compounds also exhibited anti-HCMV activity with
sub- to micromolar potencies. Importantly, these com-
pounds exhibited much less potent cytotoxic activities
than antiviral activities.
Small Molecules that Selectively Inhibit HCMV
Polymerase Subunit Interactions
As protein-protein interfaces are crucial to most biolog-
ical processes and often determine specificity, they can,
in principle, be excellent targets for drug discovery.
However, while there are numerous reports in the litera-
ture of the use of dominant negative proteins, antibodies,
or peptides to inhibit protein-protein interactions, there
are only a few examples of small ‘‘drug-like’’ molecules
that selectively disrupt these interactions. Several fac-
tors seem likely to have contributed to our ability to
add AL5, AL9, AL12, AL18, and AL21 to that number.
Although the UL54-UL44 interaction involves a number
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these are crucial. In particular, when either Leu1227 or
Phe1231 of UL54 is substituted with alanine, no detect-
able interaction between UL54 and UL44 is observed
[3]. These two residues help form a hydrophobic ‘‘plug’’
that packs against a hydrophobic crevice on UL44 [25].
It is easy to envision a small molecule being able to spe-
cifically disrupt this interaction.
It is interesting to compare the compounds identified
in this study and BP5, a small molecule that specifically
inhibits the interaction between the two subunits of
HSV-1 DNA polymerase, UL30 and UL42 [20]. BP5 has
more peptide-like qualities than does AL5, AL9, AL12,
AL18, or AL21, which include more aromatic properties.
This difference may relate to the major difference be-
tween the HSV-1 UL30-UL42 interaction, which relies
on critical hydrogen bonding interactions [26, 27], and
the HCMV UL54-UL44 interaction, which involves hydro-
phobic interactions [3, 4, 25], even though these interac-
tions both involve the C terminus of each catalytic sub-
unit and the connector loop of the other subunit. It is
therefore not surprising that BP5 does not inhibit the
HCMV UL54-UL44 interaction [20], while none of the
compounds studied here inhibited the HSV-1 UL30 pep-
tide-UL42 interaction (Figure 3B and data not shown).
These differences emphasize the highly specific nature
of these polymerase subunit interactions, which also
share no sequence homology. It is possible that these
biochemical differences contribute to the much larger
ratios of cytotoxic to antiviral concentrations of the com-
pounds studied here than that observed for BP5.
Selective Inhibitors of HCMV Replication
Because HCMV is such a serious pathogen in newborns
and in immunocompromised individuals, and because
current drugs have important toxicities and/or pharma-
cokinetic drawbacks, we were especially heartened to
observe relatively potent inhibition of HCMV replication.
The potencies observed were similar to those of GCV,
the drug of choice for the treatment of most HCMV infec-
tions [28]. They are comparable to published values for
cidofovir, for which IC50 values from 0.5 to 2.8 mM have
been described [29], and significantly greater than that
of foscarnet, for which IC50 values from 23 to 81 mM
have been reported [30]. At least as important, these
small molecules, without any modifications, exhibit cy-
totoxic activities similar to those of GCV, and only
slightly greater than those reported for foscarnet and ci-
dofovir (600 and 360 mM, respectively [23, 29]). Crystal
structures of UL44, either unliganded or bound to the
C terminus of UL54, have been solved [25, 31]. This
makes feasible studying how the compounds bind to
their target in molecular detail and using that information
to guide modifications of the compounds in order to in-
crease their antiviral activity and decrease their cytotox-
icity.
It is notable that all five of the compounds that in-
hibited long-chain DNA synthesis by the UL54/UL44
combination exhibited antiviral activity, while 15 out of
the 16 compounds that failed to inhibit long-chain DNA
synthesis also failed to inhibit HCMV replication. This
strong correlation suggests that the anti-HCMV activity
of our compounds is likely due to inhibition of viral poly-
merase subunit interactions inside infected cells. How-ever, further study is needed to determine if this is
indeed the antiviral mechanism.
The inhibitors of HCMV DNA polymerase subunit in-
teractions that we have identified may have some theo-
retical advantages when compared with other classes of
anti-HCMV compounds. First, following phosphoryla-
tion, drugs such as GCV and cidofovir mimic natural
nucleotide substrates of host enzymes, which can lead
to toxicities such as mutagenesis, as documented for
GCV [32]. The new, non-nucleoside compounds identi-
fied here would not be expected to exhibit similar toxic-
ities, although other kinds of toxicities cannot be ex-
cluded. Second, GCV, cidofovir, and foscarnet act via
inhibition at sites in HCMV DNA polymerase that are
conserved among human and viral enzymes. Indeed,
mutations that confer resistance to these compounds
usually alter such conserved residues [33]. In contrast,
compounds that inhibit protein-protein interactions are
expected to be highly specific, as protein-protein inter-
actions themselves are highly specific. In the case of
herpesvirus DNA polymerase subunit interactions, al-
though the most important residues lie in analogous re-
gions (i.e., the C terminus of the catalytic subunit and the
so-called connector loop of the accessory protein), the
sequences of these segments differ considerably.
Moreover, the side chains of the residues that have
been identified as important for HSV-1 UL30-UL42 and
for HCMV UL54-UL44 interaction are different, being hy-
drophilic in the first case [26] and hydrophobic in the
second [3, 4]. The differences between HCMV and HSV
DNA polymerase subunit interactions herald the pros-
pect that small-molecule inhibitors targeting such inter-
actions could be significantly more specific than most of
the drugs currently licensed for anti-herpesvirus chemo-
therapy. In support of this hypothesis, the small mole-
cules able to block the UL54-UL44 interaction did not
detectably inhibit the binding between the subunits of
HSV-1 polymerase (Figure 3). Furthermore, the details
of the UL54-UL44 interaction differ substantially from
those of the human processivity factor, PCNA, and its
binding partners [25]. Third, our new compounds, which
target sites on the viral polymerase different from those
targeted by GCV, cidofovir, and foscarnet, should be ac-
tive against viruses resistant to these drugs.
Thus, the small molecules that we have identified rep-
resent an interesting starting point for the discovery of
new, non-substrate-based drugs that may be more po-
tent and specific than currently existing anti-HCMV
agents, and that should be active against viral mutants
resistant to these compounds. Our results also suggest
that screening for inhibitors of viral polymerase subunit
interactions could be useful for identifying new com-
pounds active against other viral infections, including
those of importance for biodefense.
Significance
HCMV is an important pathogen in the immunocom-
promised, including transplant recipients and patients
with AIDS, and in newborns, where it is a leading in-
fectious cause of birth defects [5]. Although there
are several antiviral drugs licensed for the treatment
and prophylaxis of HCMV infections, these all suffer
from problems with toxicity, drug resistance, and/or
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cluding the frontline therapy, ganciclovir, work via
inhibition of the viral DNA polymerase by binding to
active sites that contain residues conserved among
human and viral enzymes [7]. In contrast, the residues
that comprise the interaction interface between UL54
and UL44 are not conserved with their human counter-
parts or even with counterparts from other herpesvi-
ruses. Thus, a small molecule that specifically inhibits
this interaction should avoid the kinds of toxicities ob-
served with current anti-HCMV polymerase inhibitors.
It is therefore encouraging that the molecules that we
have identified selectively inhibit HCMV polymerase
subunit interactions and exhibit sub- to low micromo-
lar potency against HCMV. Evenmore encouraging are
the relatively low potencies of these compounds in as-
says of cytotoxicity, which distinguish them from the
previously identified inhibitor of HSV DNA polymerase
subunit interactions. Indeed, even without the benefit
of any medicinal chemistry to modify these com-
pounds, their cell-based therapeutic indices are simi-
lar to that of ganciclovir. As these compounds are di-
verse in structure, and the crystal structure of UL44
both unliganded and bound to the C terminus of
UL54 have been solved, prospects for modifying at
least one of these into a safer, more potent anti-
HCMV drug seem promising. Our results also suggest
that screening for inhibitors of viral polymerase sub-
unit interactions could be useful for identifying new
compounds active against other viral infections, in-
cluding those of importance for biodefense.
Experimental Procedures
Peptides and Proteins
Unlabeled peptide 1, corresponding to the 22 C-terminal residues of
HCMV UL54 [2], and the same peptide N-terminally labeled with the
pentafluorofluorescein-derivative Oregon Green 514 (Molecular
Probes) were synthesized and HPLC-purified by C. Dahl at the
Biopolymers Facility of the Department of Biological Chemistry &
Molecular Pharmacology (Harvard Medical School). Peptide A, cor-
responding to the 36 C-terminal residues of HSV-1 UL30 [22], and
a peptide comprising the 18 C-terminal residues of HSV-1 UL30
(peptide E) and N-terminally labeled with Oregon Green 514 were
prepared as previously described [20]. The peptides were dissolved
in water, and concentrations were determined by quantitative amino
acid analysis performed by the Molecular Biology Core Facility,
Dana-Farber Cancer Institute.
The wild-type GST-UL44DC290 fusion protein, which contains the
N-terminal 290 residues of HCMV UL44, the GST-UL44DC290 I135A
mutant, and GST alone, were purified fromEscherichia coliBL21(DE3)-
pLysS harboring the appropriate plasmid, as previously described [3].
The purification of E. coli-expressed MBP-UL42DC340 fusion protein,
which contains the N-terminal 340 residues of HSV-1 UL42, has been
previously reported [26]. Purified baculovirus-expressed HCMV UL54
and UL44 proteins, prepared as previously described [2], were kindly
provided by H. S. Marsden (Institute of Virology, Glasgow, UK).
Concentrations of all proteins were determined by using quantita-
tive amino acid analysis at the Molecular Biology Core Facility,
Dana-Farber Cancer Institute.
FP Assays
Unless otherwise indicated, 3 nM of Oregon Green-labeled peptide 1
was added to 2.5 mM GST-UL44DC290 in 50 mM Tris-HCl (pH 7.5),
2 mM dithiothreitol, 0.5 mM EDTA, 150 mM NaCl, 4% glycerol, and
100 mg/ml bovine serum albumin and kept on ice until the mix was
distributed into black 384-well plates (Nunc) in a total volume of
40 ml per well. For high-throughput screening, small molecules
(5 mg/ml in DMSO) of the Maybridge, Bionet, Peakdale, ChemDiv,and Chembridge Microformat libraries were obtained from the
ICCB, and 100 nl of each compound was transferred to individual
wells using 384-pin arrays. The 21 compounds that were subse-
quently purchased for further studies were resuspended in DMSO
at a final concentration of 20 mM. All compounds were tested in du-
plicate. As controls, reaction mixtures containing either labeled pep-
tide 1 only, or GST-UL44DC290 plus labeled peptide 1 (no com-
pound), or GST-UL44DC290 plus labeled peptide 1 in the presence
of 3 mM or 20 mM of unlabeled peptide 1, were included on each
screening plate. After 15 min incubation at room temperature, FP
values (in millipolarization units) were determined by using an Ana-
lyst plate reader (LJL Biosystems).
Selected compounds were also tested in an FP assay used to de-
tect inhibitors of HSV-1 DNA polymerase subunit interactions. The
assay was conducted as previously described [20], testing various
concentrations of each compound in duplicate.
DNA Polymerase Assays
The effects of compounds were tested in a gel-based assay that
measures long-chain DNA synthesis as described previously [3],
with 5 ml of in vitro-transcribed and -translated UL54 plus 800 fmol
of GST-UL44DC290 in the absence or presence of various amounts
of each compound. The basal DNA polymerase activity of UL54 in
the absence or presence of various amounts of each compound
was measured by a filter-based assay, as previously reported [2],
but with 5 ml of in vitro-transcribed and -translated UL54, as in the
study by Loregian et al. [3]. In both assays, the final concentration
of compound-derived DMSO was maintained at 0.5% (v/v) in all
samples. In control samples (with no compound), an appropriate
volume of pure DMSO was added for a final concentration of 0.5%.
UL54-UL44 Interaction ELISA
This assay was conducted as previously described [2], testing vari-
ous concentrations of each compound. Briefly, microtiter plates
were coated with 0.2 mg of purified baculovirus-expressed UL54
and blocked with 2% bovine serum albumin (Sigma) in PBS for
1 hr. After washing, 0.5 mg of purified baculovirus-expressed UL44,
mixed with each compound at different concentrations (maintaining
a final 1% DMSO concentration) or with DMSO alone at a final 1%
concentration (no compound), was added and incubated for 1 hr
at 37ºC. Following further washes, the wells were incubated with
monoclonal antibody (MAb) YL1/2, which recognizes the EEF epi-
tope inserted at the C terminus of UL44 [2], for 1 hr at 37ºC. Plates
were then washed and incubated with horseradish peroxidase
(HRP)-conjugated anti-rat antibody (Sigma). After final washes, the
chromogenic substrate 2,20-azino-bis(3-ethylbenzothiazoline-6-
sulphonic acid) (Pierce) in citrate phosphate buffer (pH 4.0) contain-
ing 0.01% hydrogen peroxide was added and absorbance was read
at 405 nm on a Victor plate reader (Wallac).
Antiviral Assays
Plaque reduction assays were performed essentially as follows: HFF
cells were seeded at 23 105 cells per well in 24-well plates. The next
day, cells were infected with HCMV (strain AD169) at 80 PFU per well
in DMEM plus 5% FBS at 37ºC. Two hours postinfection, the inocula
were removed, cells were washed, and media containing various
concentrations of each drug tested, 5% FBS, and 0.6% methylcellu-
lose were added. All drug concentrations were tested at least in
duplicate. GCV was obtained from Sigma. After incubation at 37ºC
for 10–11 days, cell monolayers were stained with crystal violet
and plaques were counted.
For yield reduction assays, HFF cells were plated at 2 3 104 cells
per well in 96-well plates, incubated overnight, and infected with
HCMV AD169 at a multiplicity of infection of 1. After virus adsorption
for 2 hr at 37ºC, cells were washed and incubated with 200 ml of fresh
media containing test compounds at various concentrations. Plates
were incubated for 3 or 5 days at 37ºC and subjected to one cycle of
freezing and thawing, and titers were determined by transferring
100 ml aliquots from each of the wells to a fresh 96-well monolayer
culture of HFF cells, followed by 1:5 serial dilution across the plate.
Cultures were incubated for 7 days, cells were stained, and the num-
bers of plaques were determined as described above.
In both assays, the final concentration of compound-derived
DMSO was maintained at 1% (v/v) in all samples. In control samples
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199(with no compound), an appropriate volume of pure DMSO was
added for a final concentration of 1%.
Cytotoxicity Assays
HFF cells were seeded at 2 3 104, 4 3 103, or 103 cells per well into
96-well plates and, after a 3 hr incubation to allow cell attachment,
were treated for 24, 72, or 120 hr, respectively, with various concen-
trations of each compound in duplicate. The cell numbers seeded
were chosen so that untreated cells would yield an absorbance
that was near maximal within the linear range of the assay. Cell via-
bility was then determined with an XTT assay (according to the man-
ufacturer’s protocol). The values for the 120 hr assay, which started
with the smallest number of cells, reflect effects on both proliferation
and viability, while the values for the other assays mainly reflect
effects on viability. The final concentration of compound-derived
DMSO was maintained at 1% (v/v) in all samples. In control samples
(with no compound), an appropriate volume of pure DMSO was
added for a final concentration of 1%.
Acknowledgments
We thank Howard Marsden for encouragement and for kindly pro-
viding the baculovirus-expressed UL54 and UL44 proteins, Can
Cui for supplying purified MBP-UL42DC340 protein, Charles Dahl
for synthesis and purification of peptides, and personnel of the
Molecular Biology Core Facility, Dana-Farber Cancer Institute, for
peptide and protein quantification. We are especially grateful to Car-
oline Shamu, David Hayes, and James Follen of the ICCB for assis-
tance with the screen and helpful discussions, and the National Can-
cer Institute’s Initiative for Chemical Genetics, which supported the
ICCB. This work was supported by National Institutes of Health
grants AI19838 and AI26077 to D.M.C., and a PRIN 2005 grant to A.L.
Received: September 27, 2005
Revised: November 29, 2005
Accepted: December 1, 2005
Published: February 24, 2006
References
1. Loregian, A., Marsden, H.S., and Palu, G. (2002). Protein-protein
interactions as targets for antiviral chemotherapy. Rev. Med.
Virol. 12, 239–262.
2. Loregian, A., Rigatti, R., Murphy, M., Schievano, E., Palu, G., and
Marsden, H.S. (2003). Inhibition of human cytomegalovirus DNA
polymerase by C-terminal peptides from the UL54 subunit.
J. Virol. 77, 8336–8344.
3. Loregian, A., Appleton, B.A., Hogle, J.M., and Coen, D.M. (2004).
Residues of human cytomegalovirus DNA polymerase catalytic
subunit UL54 that are necessary and sufficient for interaction
with the accessory protein UL44. J. Virol. 78, 158–167.
4. Loregian, A., Appleton, B.A., Hogle, J.M., and Coen, D.M. (2004).
Specific residues in the connector loop of the human cytomeg-
alovirus DNA polymerase accessory protein UL44 are crucial for
interaction with the UL54 catalytic subunit. J. Virol. 78, 9084–
9092.
5. Pass, R.F. (2001). Cytomegalovirus. In Fields Virology, Volume 2,
Fourth Edition, D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb,
M.A. Martin, B. Roizman, and S.E. Straus, eds. (Philadelphia:
Lippincott, Williams, & Wilkins), pp. 2675–2705.
6. Trincado, D.E., Scott, G.M., White, P.A., Hunt, C., Rasmussen,
L., and Rawlinson, W.D. (2000). Human cytomegalovirus strains
associated with congenital and perinatal infections. J. Med.
Virol. 61, 481–487.
7. Yeh, R., and Coen, D.M. (2004). Pharmacology of viral replica-
tion. In Principles of Pharmacology: The Pathophysiologic Basis
of Drug Therapy, D.E. Golan, A.H. Tashjian, E.J. Armstrong, J.M.
Galanter, A.W. Armstrong, R.A. Arnaout, and H.S. Rose, eds.
(Baltimore: Lippincott, Williams, & Wilkins), pp. 545–564.
8. Villarreal, E.C. (2003). Current and potential therapies for the
treatment of herpes-virus infections. Prog. Drug Res. 60, 263–
307.
9. Archakov, A.I., Govorun, V.M., Dubanov, A.V., Ivanov, Y.D.,
Veselovsky, A.V., Lewi, P., and Janssen, P. (2003). Protein-pro-tein interactions as a target for drugs in proteomics. Proteomics
3, 380–391.
10. Tsai, C.J., Lin, S.L., Wolfson, H.J., and Nussinov, R. (1997). Stud-
ies of protein-protein interfaces: a statistical analysis of the
hydrophobic effect. Protein Sci. 6, 53–64.
11. Cunningham, B.C., and Wells, J.A. (1997). Minimized proteins.
Curr. Opin. Struct. Biol. 7, 457–462.
12. Thomas, M.C., Ballantine, S.P., Bethell, S.S., Bains, S., Kellam,
P., and Delves, C.J. (1998). Single amino acid substitutions dis-
rupt tetramer formation in the dihydroneopterin aldolase en-
zyme of Pneumocystis carinii. Biochemistry 37, 11629–11636.
13. Nishiyama, Y., Maeno, K., and Yoshida, S. (1983). Characteriza-
tion of human cytomegalovirus-induced DNA polymerase and
the associated 30-to-50, exonuclease. Virology 124, 221–231.
14. Ertl, P.F., and Powell, K.L. (1992). Physical and functional inter-
action of human cytomegalovirus DNA polymerase and its ac-
cessory protein (ICP36) expressed in insect cells. J. Virol. 66,
4126–4133.
15. Weiland, K.L., Oien, N.L., Homa, F., and Wathen, M.W. (1994).
Functional analysis of human cytomegalovirus polymerase ac-
cessory protein. Virus Res. 34, 191–206.
16. Ripalti, A., Boccuni, M.C., Campanini, F., and Landini, M.P.
(1995). Cytomegalovirus-mediated induction of antisense
mRNA expression to UL44 inhibits virus replication in an astro-
cytoma cell line: identification of an essential gene. J. Virol. 69,
2047–2057.
17. Pari, G.S., and Anders, D.G. (1993). Eleven loci encoding trans-
acting factors are required for transient complementation of
human cytomegalovirus oriLyt-dependent DNA replication.
J. Virol. 67, 6979–6988.
18. Pari, G.S., Kacica, M.A., and Anders, D.G. (1993). Open reading
frames UL44, IRS1/TRS1, and UL36-38 are required for transient
complementation of human cytomegalovirus oriLyt-dependent
DNA synthesis. J. Virol. 67, 2575–2582.
19. Arkin, M.R., and Wells, J.A. (2004). Small-molecule inhibitors of
protein-protein interactions: progressing towards the dream.
Nat. Rev. Drug Discov. 3, 301–317.
20. Pilger, B.D., Cui, C., and Coen, D.M. (2004). Identification of
a small molecule that inhibits herpes simplex virus DNA poly-
merase subunit interactions and viral replication. Chem. Biol.
11, 647–654.
21. Dandliker, W.B., Hsu, M.L., Levin, J., and Rao, B.R. (1981). Equi-
librium and kinetic inhibition assays based upon fluorescence
polarization. Methods Enzymol. 74, 3–28.
22. Digard, P., Williams, K.P., Hensley, P., Brooks, I.S., Dahl, C.E.,
and Coen, D.M. (1995). Specific inhibition of herpes simplex vi-
rus DNA polymerase by helical peptides corresponding to the
subunit interface. Proc. Natl. Acad. Sci. USA 92, 1456–1460.
23. Faulds, D., and Heel, R.C. (1990). Ganciclovir: a review of its
antiviral activity, pharmacokinetic properties and therapeutic
efficacy in cytomegalovirus infections. Drugs 39, 597–638.
24. Stinski, M.F. (1983). Molecular biology of cytomegaloviruses. In
Herpesviruses, Volume 2, B. Roizman, ed. (New York: Plenum
Press), pp. 67–113.
25. Appleton, B.A., Brooks, J., Loregian, A., Filman, D.J., Coen,
D.M., and Hogle, J.M. (2005). The crystal structure of the cyto-
megalovirus DNA polymerase subunit UL44 with the C terminus
from the catalytic subunit: differences in structure and function
relative to unliganded UL44. J. Biol. Chem., in press. Published
online December 20, 2005. 10.1074/jbc.M506900200.
26. Bridges, K.G., Chow, C.S., and Coen, D.M. (2001). Identification
of crucial hydrogen-bonding residues for the interaction of her-
pes simplex virus DNA polymerase subunits via peptide display,
mutational, and calorimetric approaches. J. Virol. 75, 4990–
4998.
27. Zuccola, H.J., Filman, D.J., Coen, D.M., and Hogle, J.M. (2000).
The crystal structure of an unusual processivity factor, herpes
simplex virus UL42, bound to the C terminus of its cognate poly-
merase. Mol. Cell 5, 267–278.
28. Markham, A., and Faulds, D. (1994). Ganciclovir: an update of its
therapeutic use in cytomegalovirus infection. Drugs 48, 455–
484.
29. Snoeck, R., Sakuma, T., De Clercq, E., Rosenberg, I., and Holy, A.
(1988). (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine,
Chemistry & Biology
200a potent and selective inhibitor of human cytomegalovirus repli-
cation. Antimicrob. Agents Chemother. 32, 1839–1844.
30. Andrei, G., Snoeck, R., Schols, D., Goubau, P., Desmyter, J., and
De Clercq, E. (1991). Comparative activity of selected antiviral
compounds against clinical isolates of human cytomegalovirus.
Eur. J. Clin. Microbiol. Infect. Dis. 10, 1026–1033.
31. Appleton, B.A., Loregian, A., Filman, D.J., Coen, D.M., and Ho-
gle, J.M. (2004). The cytomegalovirus DNA polymerase subunit
UL44 forms a C clamp-shaped dimer. Mol. Cell 15, 233–244.
32. Morris, D.J. (1994). Adverse effects and drug interactions of clin-
ical importance with antiviral drugs. Drug Saf. 10, 281–291.
33. Coen, D.M. (1996). Viral DNA polymerases. In Eukaryotic DNA
Replication, M.L. DePamphilis, ed. (Cold Spring Harbor, NY:
Cold Spring Harbor Laboratory Press), pp. 495–523.
